Please assess the completion status of the following clinical trial:

Trial Title: AdV-tk Therapy With Surgery and Chemoradiation for Pancreas Cancer (PaTK01)

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Must have presumed pancreatic adenocarcinoma based on clinical and radiologic evaluation with identifiable tumor accessible for injection (pathologic diagnosis of pancreatic adenocarcinoma must be made prior to AdV-tk injection~* For Arm A, resectable disease. Arm B for locally advanced disease has completed accrual.~* Performance status must be ECOG 0-2~* SGOT (AST)\<3x upper limit of normal~* Serum creatinine\<2mg/dl and calculated creatinine clearance \>10ml/min~* Platelets\>100,000/mm3 and WBC\>3000/mm3 and ANC\>1500/mm3~* Must give study specific informed consent prior to enrollment~Exclusion Criteria:~* Primary hepatic dysfunction including active hepatitis but not to exclude patients due to obstructive jaundice. If obstructive jaundice is clinically significant, bilirubin should be stable or decreasing prior to enrollment.~* Evidence of clinically significant pancreatitis as determined by the investigator.~* Patients on corticosteroids or other immunosuppressive drugs~* Known HIV+ patients~* Patients with acute infections (viral, bacterial or fungal infections requiring therapy)~* Pregnant or breast-feeding patients. Female patients of childbearing age must have negative serum or urine pregnancy test within 1 week of beginning therapy~* Evidence of distant metastatic disease at the time of enrollment or other malignancy (except squamous or basal cell skin cancers) and no prior abdominal radiation therapy or prior treatment for pancreatic cancer~* Other serious co-morbid illness or compromised organ function

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- A resectable (Type: EXPERIMENTAL): Arm A is for resectable tumors. The first AdV-tk course is given prior to surgery by CT or EUS guided injection into the tumor followed by 14 days of valacyclovir. The second AdV-tk injection is into the tumor bed at the time of surgery again followed by 14 days of valacyclovir.
- B locally advanced (Type: EXPERIMENTAL): Arm B is for locally advanced tumors for which chemoradiation is the planned standard of care treatment. AdV-tk is delivered by CT or EUS guided injection into the tumor. The first AdV-tk injection is given prior to starting chemoradiation and the second in week 3 of chemoradiation. Both injections are followed by 14 days of valacyclovir.~Enrollment has been completed for Arm B.

Based on this trial design, predict the completion outcome and termination type (if applicable).